Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.0090 AUD
Change Today 0.00 / 0.00%
Volume 0.0
SBN On Other Exchanges
Symbol
Exchange
OTC US
As of 10:54 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

sun biomedical ltd (SBN) Snapshot

Open
A$0.0090
Previous Close
A$0.0090
Day High
A$0.0090
Day Low
A$0.0090
52 Week High
07/16/15 - A$0.01
52 Week Low
12/29/14 - A$0.0050
Market Cap
11.9M
Average Volume 10 Days
451.7K
EPS TTM
A$-0.0016
Shares Outstanding
1.3B
EX-Date
02/28/00
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SUN BIOMEDICAL LTD (SBN)

Related News

No related news articles were found.

sun biomedical ltd (SBN) Related Businessweek News

No Related Businessweek News Found

sun biomedical ltd (SBN) Details

Sun Biomedical Limited, a biotechnology company, develops and commercializes drug therapies and drug discovery tools. Its lead therapeutic product includes DMX200, for treating patients with chronic kidney diseases. The company also develops DMX250 to treat chronic kidney disease. In addition, it offers Receptor-HIT, a cell-based drug discovery assay technology to assist third parties in drug discovery and development processes through contract research. The company was founded in 2004 and is based in Melbourne, Australia.

Founded in 2004

sun biomedical ltd (SBN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sun biomedical ltd (SBN) Key Developments

Dimerix Bioscience Receives Human Ethics Committee Approval to Commence Phase II Clinical Trial of DMX200 in Patients with Chronic Kidney Disease

Dimerix Bioscience Limited announced receipt of ethics committee approval under the Clinical Trial Notification scheme of the Australian Therapeutic Goods administration to commence its Phase II clinical trial of DMX200 in patients with Chronic Kidney Disease. Recruitment of patients at the Austin Hospital is expected to commence shortly. The study will investigate the effect of DMX200 on proteinuria in patients with pre existing chronic kidney disease. The DMX200 treatment involves patients who are currently treated with irbesartan, an angiotensin receptor blocker, also taking propagermanium, an anti-inflammatory molecule which acts through the chemokine 2 receptor. The study will be completed under the supervision of Professor David Power, Director of Nephrology at the Austin Hospital, as Principal Investigator. The therapeutic rationale for DMX200 was developed from Dimerix’s core patented technology, known as Receptor – Heteromer Identification Technology (Receptor – HIT) which can be used to elucidate receptor (or drug target) interactions. Applying this technology to receptors such as G-protein coupled receptors (GPCR’s), Dimerix is able to identify differences in signalling behaviour when receptors interact as heteromers, as expected in vivo, compared with the traditional analysis of single target receptors in isolation.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SBN:AU A$0.01 AUD 0.00

SBN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SBN.
View Industry Companies
 

Industry Analysis

SBN

Industry Average

Valuation SBN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUN BIOMEDICAL LTD, please visit www.dimerix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.